Inflamalps SA

Inflamalps has been based at BioArk since its creation in 2012 by Vincent Mutel, an entrepreneur who has worked in the field of life sciences for many years. It develops new drugs to treat certain inflammatory diseases of the eye, particularly dry eye syndrome, which affects between 4% and 7% of the population worldwide.

Activities and products

In ophthalmology, there is an urgent need to develop new treatments to combat chronic inflammatory diseases. Inflamalps is tackling this, focusing on dry eye syndrome and uveitis. In the developed world, dry eye syndrome is directly or indirectly associated with 60% of recorded cases of loss of visual acuity, and uveitis is one of the leading causes of blindness.

In order to combat these diseases, Inflamalps is working on the development of new drugs to control some of the agents involved in regulating immune functions.

Inflamalps, which successfully obtained its initial funding in 2015, will carry out its first trials on humans in 2017 and plans to market its products mainly in Europe and the United States. However, a partnership has been established with a Chinese laboratory that specialises in ophthalmology and has a clinical and marketing network.

Inflamalps started life within The Ark's Incubator, and, depending on the nature of its projects, still receives occasional support from The Ark Foundation.